This week's biggest % winners & losers: March 2 - 6, 20 (wk 10)

The following are this week's top percentage gainers and losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top % gainers

• Healthcare: INO (14.09 +229.21%), FTSV (94.35  +62.67), OPK (2.32 +54.67%), KPTI (25.02 +53.12%), OMER (18.08 +51.81%), BCRX (4.11 +37%), FIXX (20.78 +29.88%), RCUS (19.28 +26.68%), ANAB (18.23 +21.94%), IOVA (38.85 +18.05%)
• Materials: AU (21.06 +20.69%)
• Industrials: AVAV (61.15 +18.99%)
• Energy: EXTN (6.58 +29.02%)
• Consumer Staples: BJ (23.91 +24.14%), RAD (16.15 +18.58%)

This week's top % losers

• Healthcare: SGRY (10.76 -34.47%)
• Consumer Discretionary: AGS (6.21 -35.91%), HUD (6.23 -33.08%), ERI (33.65 -32.94%), RRGB (18.5 -32.73%)
• Energy: CPE (1.3 -42.73%), SM (3.82 -41.86%), KOS (1.95 -36.07%), QEP (1.44 -36%), CDEV (1.52 -35.86%), TELL (1.21 -32.78%), DO (2.06 -32.46%)

-=Long trade : Karyopharm Therapeutics Inc. (KPTI) +50% (3/20)

Karyopharm's stock jumps on trial results for multiple myeloma combo candidate


Shares of Karyopharm Therapeutics Inc. (KPTI) soared 65% in trading on Monday after the drugmaker said an experimental combination treatment for multiple myeloma met its primary endpoint in a late-stage clinical trial. The combination pairs Karyopharm's Xpovio, which received Food and Drug Administration approval in mid-2019, with Velcade and low-dose dexamethasone. Velcade is marketed by Takeda Pharmaceutical Company Ltd. (TAK). The progression-free survival was about 14 months, up from about nine months reported by patients undergoing the standard of care. A number of new multiple myeloma treatments have come to market in recent years, including Sanofi's (SNY) Sarclisa, which received FDA approval on Sunday. Karyopharm's stock is up 525% over the past year, compared with the Health Care Select Sector SPDR Fund XLV, -0.53%, which has gained 1%.